NZ523676A - Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease - Google Patents

Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease

Info

Publication number
NZ523676A
NZ523676A NZ523676A NZ52367601A NZ523676A NZ 523676 A NZ523676 A NZ 523676A NZ 523676 A NZ523676 A NZ 523676A NZ 52367601 A NZ52367601 A NZ 52367601A NZ 523676 A NZ523676 A NZ 523676A
Authority
NZ
New Zealand
Prior art keywords
irritable bowel
cetyl
treat
bowel disease
myristate
Prior art date
Application number
NZ523676A
Inventor
Timothy David Meakin
Craig Leonard Heatley
Dianne Adwallader
Original Assignee
Meracol Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meracol Corp Ltd filed Critical Meracol Corp Ltd
Priority to NZ523676A priority Critical patent/NZ523676A/en
Publication of NZ523676A publication Critical patent/NZ523676A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A cetyl myristate and cetyl palmitate mixture, useful for the treatment or prophylaxis of irritable bowel syndrome and/or irritable bowel disease.
NZ523676A 2001-05-11 2001-05-11 Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease NZ523676A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ523676A NZ523676A (en) 2001-05-11 2001-05-11 Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ52298101A NZ522981A (en) 2001-05-11 2001-05-11 Treating irritable bowel syndrome or disease
NZ523676A NZ523676A (en) 2001-05-11 2001-05-11 Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease

Publications (1)

Publication Number Publication Date
NZ523676A true NZ523676A (en) 2003-03-28

Family

ID=19928944

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ523676A NZ523676A (en) 2001-05-11 2001-05-11 Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease
NZ52298101A NZ522981A (en) 2001-05-11 2001-05-11 Treating irritable bowel syndrome or disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ52298101A NZ522981A (en) 2001-05-11 2001-05-11 Treating irritable bowel syndrome or disease

Country Status (1)

Country Link
NZ (2) NZ523676A (en)

Also Published As

Publication number Publication date
NZ522981A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
TNSN04113A1 (en) 3-รข-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
MY136707A (en) Thrombopoietin mimetics
GB0005251D0 (en) Therapeutic compounds
DE69831506D1 (en) 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
MXPA02011288A (en) Substituted thioacetamides.
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
GB0225475D0 (en) Therapeutic agents
GB0025173D0 (en) Therapeutic agents
TW200505434A (en) Therapeutic treatment
MXPA03001645A (en) Compositions and methods for the diagnosis and treatment of tumor.
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
GB0225474D0 (en) Therapeutic agents
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU5624699A (en) Use of 5ht-6 antagonists
BR0309095A (en) Use of osteoprotegerin for the treatment and / or prevention of fibrotic disease.
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
EP0909561A3 (en) Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder
CA2408537A1 (en) Treating irritable bowel syndrome or disease
DE60013486D1 (en) LINKS
RS8504A (en) Novel cyclohexil sulphones
MXPA02009705A (en) New combination of a betablocker and a cholesterol lowering agent.
GB0020504D0 (en) Therapeutic method
HUP0002836A2 (en) Use of macrocyclic bis(3,3'-indolyl)-maleimide derivatives for the preparation of pharmaceutical compositions treating skin disorders
MXPA02011511A (en) USE OF (plus;) agr; (2, 3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDIN EMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS.
MY124071A (en) Treatment of viral disease in swine

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ERR Error or correction

Free format text: THE FILED DATE HAS BEEN CORRECTED TO 12/05/2000

Effective date: 20131025

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 11 MAY 2021 BY LEA SKYLLERSTEDT

Effective date: 20140430

EXPY Patent expired